VivoSeq
Neurology

Spinocerebellar Ataxia Type 2

2

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Spinocerebellar Ataxia Type 2 is an early-stage landscape with 2 programs across 4 companies. The most active players are Arrowhead Pharmaceuticals, Eli Lilly, Azurity Pharmaceuticals. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Arrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

1 program

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 3S

Solvay Pharmaceuticals

1 program

Approved

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Riluzole

Azurity Pharmaceuticals

Approved1

Lithium Carbonate

Solvay Pharmaceuticals

Analysis

Trial Status

2

clinical trials

Completed1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03347344·42 enrolled
A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar Ataxia Type 2
Active, not recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 1·NCT06672445·39 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)